HSP90AA1 and non-small cell lung carcinoma: The combined treatment of NSCLC and lung adenocarcinoma cells with pemetrexed and with the 17-AAG Hsp90 inhibitor results in an enhanced pemetrexed-induced cytotoxic effect.